Yield10 Bioscience, Inc. (YTEN) Misses Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Yield10 Bioscience Announces Fourth Quarter and Full Year 2020 Financial Results
March 16, 2021 4:05 PM EDTWOBURN, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today reported financial results for the three and twelve months ended December 31, 2020.
"In 2020 we continued to execute our business plan, and successfully achieved key milestones required to utilize Camelina as a platform crop to produce fuel, food and PHA bioplastic," said Oliver Peoples, Ph.D., president and chief executive officer of Yield10 Bioscience. Among our key accomplishments in 2020 was securing the collaboration with Rothamsted Research for the exclusive option to commercialize advanced omega-3 (DHA+EPA) technology... More
